



ESP CASE DETECTION ALGORITHM

Chlamydia

Document Version 2.0

Prepared by the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute on behalf of the Massachusetts Department of Public Health.

esphealth@harvardpilgrim.org

June 20, 2016

Modification History

| Version | Date | Modification | Ву |
|---------|------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| 2.0 | 10/16/2017 | Updated documentation format and added ESP Logo and MDPH branding Updated test of reinfection documentation Added EPT documentation | DPM/CII |
| 1.4 | 6/20/2016 | Updated recurrence interval and windows for "reportables" from 28 days to 30 days per DPH request. | CII |
| 1.3 | 10/1/2015 | Incorporating review on reportable symptoms by DPH and Dr. Klompas | CII |
| 1.2 | 9/2015 | Updated medication reporting, ICD10 | CII |
| 1.1 | 12/18/2014 | Updates to bring in line with current code | CII |
| 1.0 | | Initial Draft | ESP Working group |





Section 1. Overview

The purpose of this document is to describe the criteria used to identify and report chlamydia cases from electronic medical records (EMR) using ESP and report them to the Massachusetts Department of Public Health (MDPH).

Section 2. Criteria used to identify cases using ESP data

I. CASE TYPES

This document includes an algorithm to identify incident and recurrent chlamydia cases.

II. TIME WINDOW

The recurrence interval for chlamydia is 30 days.

III. CASE CRITERIA

Cases are defined as patients with result "positive" or "detected" or abnormal flag activated for urine, urethral, cervical, or rectal test for chlamydia by culture or nucleic acid amplification test.

IV. CRITERIA TO REVOKE A CASE

None.

Section 3. Specifications for reporting diseases/conditions to the Massachusetts Department of Public Health

I. INITIAL CASE REPORTING CRITERIA

All cases should be immediately reported to MDPH upon initial detection.

II. CASE REPORT UPDATE CRITERIA

An updated report should be set to MDPH if a chlamydia medication (see section 4 for details) was prescribed.

Test of Reinfection*

If test of reinfection is configured at a given site, an updated report should be sent to MDPH if a chlamydia test for reinfection with any result (positive, negative, indeterminate) occurs from day 31 through day 180 following the initial positive test.

Notes:

- 1. Only the first chlamydia test from day 31 to day 180 following the result date of the initial positive chlamydia test is reported.
- 2. The ESP tests associated with chlamydia are used to identify tests of reinfection (see <u>Section 4, Table 1</u>).
- 3. The result of the follow-up test (positive, negative, indeterminate) is reported.





4. Test of reinfection reporting is in addition to routine, case reporting for the first Chlamydia test. Hence, it is possible that a single positive case may be reported twice: once as a conventional positive Chlamydia case and again as a positive test of reinfection if the patient had a positive Chlamydia within the preceding 180 days. The new positive case in turn needs to be followed for test of reinfection for the next 180 days.

Expedited Partner Therapy (EPT)*

If EPT is configured at a given site, an updated report should be sent to MDPH if

*Only applicable to ESP sites with test of reinfection configuration.

III. DATA TO INCLUDE IN INITIAL REPORTS TO MDPH

Once a patient is identified, gather the following data to generate a report:

A. Demographic

| Name | Last, first, middle | |
|------------------------------------------------------------|-----------------------------------|--|
| Date of birth | yyyy/mm/dd | |
| Social security number | Last 4 digits | |
| Gender | Male / Female | |
| Race American Indian / Asian / Black / White / Other / Unk | | |
| Ethnicity | Hispanic / Non-Hispanic / Unknown | |
| Address Line 1, line 2, city, state, zip, country | | |
| Phone | XXX-XXXX | |
| Language spoken | | |
| Medical record number | | |
| PCP Name, office address, phone number, email | | |

B. Ordering Facility Information

| Facility name | |
|-------------------------|----------------------------------|
| Facility address | Line 1, line 2, city, state, zip |
| Facility contact person | |
| Contact person email | |
| Contact person phone | xxx-xxx-xxxx |
| Facility phone | XXX-XXX-XXXX |

C. Encounter data

| Test ordering clinician | Name, office address, phone number, email |
|-------------------------|-------------------------------------------|
| Treating clinician | Name, office address, phone number, email |

D. Laboratory Results

| Date specimen obtained | yyyy/mm/dd |
|-----------------------------|-----------------------------------------|
| LOINC code of positive test | LOINC (See <u>Table 1</u> for examples) |
| Specimen source | Urine, urethra, cervix, rectum |
| Result | SNOMED |

ESP Case Detection Algorithm - Chlamydia: Version 2.0





E. Pregnancy

| Pregnancy flag active | Yes or No. If EpicCare pregnancy flag active then pregnancy = yes. |
|------------------------------|--------------------------------------------------------------------|
| Expected date of confinement | =EDC |
| Number of weeks pregnant | =40 – [(EDC – present date) / 7] |

F. Symptoms

If any of the following diagnosis codes (see <u>Table 2</u>, below) or vital sign findings are present in the 14 days preceding or 30 days following the positive culture report then symptoms=yes, otherwise symptoms=no and the following symptoms are reported.

| Fever | Diagnosis code or measured temperature >100.4 degrees Fahrenheit | |
|------------------------------|------------------------------------------------------------------|--|
| Urethral discharge | | |
| Urethritis | | |
| Vaginitis | | |
| Cervicitis | | |
| Vaginal leucorrhea | | |
| Abdominal pain | | |
| Chlamydia | | |
| Contact with Exposure to STI | | |
| Screening for STIs | | |

G. Medications

Report all of the medications from the specified chlamydia medications list (see <u>Table 3</u>, below) given at any point from 7 days prior to the lab order date until 30 days after the positive test result date.

| Treatment given | Yes or No |
|---------------------------------------|-----------------------------------------------------------|
| Date of treatment | yyyy/mm/dd |
| Prescription for chlamydia medication | See Table 3. Report drug name, dose, route, and duration. |

Section 4. Codes, laboratory tests, and medications used to identify criteria listed in Section 2 and supplementary reporting information in Section 3.

I. LABORATORY TESTS

The following is an example of possible chlamydia lab tests and their mappings from test name to LOINC. All tests must be mapped in ESP.

Table 1. Laboratory Test LOINC Mapping

| Table 1. Laboratory Test LOINC Mapping | | | |
|----------------------------------------|---------|---------------------------------------------------------------------------|--|
| Component Name | LOINC | LOINC Name | |
| CHLAMYDIA TRACHOMATIS CULTURE | 6349-5 | Chlamydia trachomatis : ACnc : Pt : XXX : Ord : Organism specific culture | |
| CHLAMYDIA GENPROBE DNA | 20993-2 | C trach DNA XXX QI Prb | |
| CHLAMYDIA TR DNA | 21613-5 | C trach DNA XXX QI PCR | |
| PEDIATRIC URINE CHLAMYDIA | 16601-7 | C trach DNA XXX QI PCR | |
| DIRECT CHLAMYDIA/GC DETECTION | 36902-5 | Chlamydia Trachomatis+Neisseria Gonorrhoeae DNA : ACnc : Pt : xx | |

1





| CHLAMYDIA TRACH RRNA | 4993-2 | C trach rRNA XXX QI Prb |
|----------------------|--------|-------------------------|
|----------------------|--------|-------------------------|

NOTE: the result POSITIVE or DETECTED can be truncated in EpicCare at 7 letters

II. DIAGNOSES CODES

Table 2. Diagnosis Codes Used to Identify Symptoms

| Symptom | Code Type | Code | Description |
|--------------------|-----------|--------------------|-------------------------------------------------------------|
| | N/A | Temperature >100.4 | Measured temperature if available, ELSE "fever". |
| Fever | ICD-9-CM | 780.60, 780.6 | Fever |
| | ICD-10-CM | R50.9 | Fever, unspecified |
| | ICD-9-CM | 788.7 | Urethral discharge |
| Urethral discharge | ICD-10-CM | R36.0 | Urethral discharge without blood |
| J | ICD-10-CM | R36.9 | Urethral discharge, unspecified |
| | ICD-9-CM | 099.40 | Urethritis, nonspecific, |
| I I wa tha witi a | ICD-9-CM | 597.80 | Urethritis, unspecified, |
| Urethritis | ICD-10-CM | N34.1 | Nonspecific urethritis |
| | ICD-10-CM | N34.2 | Other urethritis |
| | ICD-9-CM | 616.10 | Vaginitis, unspecified |
| | ICD-10-CM | N76.0 | Acute vaginitis |
| Vaginitis | ICD-10-CM | N76.1 | Subacute and chronic vaginitis |
| | ICD-10-CM | N76.2 | Acute vulvitis |
| | ICD-10-CM | N76.3 | Subacute and chronic vulvitis |
| 0 | ICD-9-CM | 616.0 | Cervicitis |
| Cervicitis | ICD-10-CM | N72 | Inflammatory disease of cervix uteri |
| ., | ICD-9-CM | 623.5 | Vaginal leucorrhea |
| Vaginal leucorrhea | ICD-10-CM | N89.8 | Other specified noninflammatory disorders of vagina |
| | ICD-9-CM | 789.07 | Abdominal pain, generalized |
| | ICD-10-CM | R10.84 | Generalized abdominal pain |
| | ICD-9-CM | 789.04 | · |
| | ICD-10-CM | R10.32 | Left lower quadrant pain |
| | ICD-9-CM | 789.09 | · · · · |
| | ICD-10-CM | R10.10 | Upper abdominal pain, unspecified |
| Abdominal pain | ICD-10-CM | R10.2 | Pelvic and perineal pain |
| | ICD-10-CM | R10.30 | Lower abdominal pain, unspecified |
| | ICD-9-CM | 789.03 | |
| | ICD-10-CM | R10.31 | Right lower quadrant pain |
| | ICD-9-CM | 789.00 | Abdominal pain, unspec site |
| | ICD-10-CM | R10.9 | Unspecified abdominal pain |
| | ICD-9-CM | 099.54 | Chlamydia |
| Chlamydia | ICD-10-CM | A56.19 | Other chlamydial genitourinary infection |
| <u> </u> | ICD-9-CM | V01.6 | Contact with Exposure to STI |
| Contact with | ICD-10-CM | Z20.2 | Contact with and (suspected) exposure to infections with a |
| Exposure to STI | | | predominantly sexual mode of transmission |
| | ICD-9-CM | V74.5 | Screening for STIs |
| Screening for STIs | ICD-10-CM | Z11.3 | Encounter for screening for infections with a predominantly |
| - 0 | | | sexual mode of transmission |

III. MEDICATIONS





Table 3. Chlamydia Medications

| Table 3. Chiamyula Medications |
|---------------------------------------|
| Treatment |
| azithromycin 1g PO x 1 |
| azithromycin 2g PO x 1 |
| levofloxacin 250mg PO qd x ≥7 days |
| levofloxacin 500mg PO qd x ≥7 dyas |
| ofloxacin 300mg PO BID x ≥7 days |
| ciprofloxacin 500mg PO (any duration) |
| doxycycline 100mg PO x ≥7 days |
| eryrthromycin 500mg PO qid x 7 days |
| amoxicillin 500mg PO tid x 7 days |
| EES 800mg PO QID x 7 days |
| azithromycin 1g PO x 1 |
| azithromycin 2g PO x 1 |
| levofloxacin 250mg PO qd x ≥7 days |
| levofloxacin 500mg PO qd x ≥7 dyas |